The purpose of this study is to see:
1. If using these two drugs (carfilzomib and belatacept) together is safe
2. If the use of these two study drugs in addition to the usual immunosuppression for kidney transplant patients can improve your transplanted kidney function by lowering the antibodies you have against your transplanted kidney
3. If the study drugs effect the immune cells that were responding to your donor kidney. And, whether blood or urine tests can measure signs of inflammation and kidney cell injury
4. If using new computer techniques can help describe important changes seen on biopsy in your donated kidneys
The primary objective is to assess the efficacy of carfilzomib and belatacept therapy when added to current treatment with steroids and maintenance immunosuppression, compared to conventional treatment alone, to improve the clinical outcome of renal transplant patients with active and chronic - active ABMR occurring more than 6 months after renal transplantation or less than 6 months post-transplant with persistent refractory Antibody-Mediated Rejection (ABMR)

开始日期2025-06-30

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT06892522

/ Not yet recruiting临床1期

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig in adult participants with MM.
Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 4 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants will receive escalating doses of etentamig alone or in combination with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R). This will be followed by etentamig at the dose levels established during the escalation phases alone or in combination with DR, Kd, R. The participants can also receive daratumumab, lenalidomide and dexamethasone (DRd), R, or daratumumab, carfilzomib, and dexamethasone (DKd) as a comparator in the dose expansion phases. Around 440 adult participants with MM will be enrolled at approximately 50 sites worldwide
In all substudies, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or in combination with DR, R or Kd, followed by IV infusions of etentamig at the dose levels established during the escalation phases alone or in combination with IV and oral DRd, DKd, or R. The study duration is approximately 130 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

开始日期2025-06-02

申办/合作机构

AbbVie, Inc.

NCT07015021

/ Not yet recruitingN/AIIT

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients: a Randomized, Open Label, Single Arm, Single Center Clinical Study

This study is a prospective, single center, single arm phase II clinical trial. The study population consists of patients who have received treatment with VRd or VRd lite regimens for 2-8 courses in the past and have achieved therapeutic effects, but have progressed during treatment (primary refractory), experienced clinical recurrence for the first time after treatment, or progressed or recurred after the first transplant (without entering maintenance therapy). 72 patients are planned to be enrolled and receive 4 courses of induction therapy with D-KPd regimen for the first efficacy evaluation. For patients with ≥ SD, if the patient has ≥ PR and is suitable for ASCT, ASCT treatment will be given. For patients with

开始日期2025-06-01

申办/合作机构

苏州大学附属第一医院

100 项与卡非佐米相关的临床结果

登录后查看更多信息

100 项与卡非佐米相关的转化医学

登录后查看更多信息

100 项与卡非佐米相关的专利（医药）

登录后查看更多信息

2,570

项与卡非佐米相关的文献（医药）

2025-09-01·TUBERCULOSIS

In vitro and in vivo antibacterial activity of sudapyridine (WX-081) combined with other drugs against Mycobacterium abscessus

Article

作者: Fu, Lei ; Lu, Yu ; Chen, Xiaoyou ; Dong, Shaoyu ; Zheng, Luyao ; Zhang, Weiyan ; Wang, Hong

The management of Mycobacterium abscessus (MAB) infection presents formidable challenges, necessitating the development of innovative antimicrobial agents and more efficacious combination therapies. The objective of this study was to investigate the in vitro, intracellular, and in vivo antibacterial activity of sudapyridine (WX-081) in combination with clarithromycin (CLR), clofazimine (CFZ), rifabutin (RFB), and linezolid (LZD) against MAB. In vitro, the interaction between WX-081 and other drugs was assessed using the checkerboard method against MAB. Synergistic or additive effects were observed when combining WX-081 with other drugs against all strains tested. The intracellular activity of WX-081 in combination with CLR, CFZ, RFB, and LZD against the MAB reference strain in J774A.1 cells was evaluated. The combination of WX-081 and CFZ or RFB exhibited potent inhibitory activity against MAB in macrophages. To evaluate pharmacodynamics, immunosuppressed BALB/c mice were infected with MAB to establish a murine model for assessing two-drug and three-drug combinations. In vivo studies demonstrated that the combination of WX-081 with CLR or both CLR and CFZ displayed antibacterial activity and significantly prevented mouse mortality. Our study demonstrates that the concurrent use of WX-081 with CLR or CLR plus CFZ holds significant promise as a clinical intervention for MAB infection.

2025-08-01·TRANSFUSION AND APHERESIS SCIENCE

Combined use of Carfilzomib and plasmapheresis in antibody-mediated liver transplant rejection

Article

作者: Jamal, Yaseen Ali ; Yunce, Muharrem ; Wali, Junaid ; Zhang, Melody ; Virk, Mrigender Singh ; Shin, Christopher

Antibody-mediated rejection (AMR) poses significant challenges in liver transplant patients, and treatment guidelines recommend variable approaches which usually combine therapeutic plasma exchange (TPE) with immunosuppression therapies without standardized protocols [1]. Here we report two patients with AMR post-liver transplant refractory to multiple treatment regimens who were consequently treated with a combination of Carfilzomib and TPE. Patient 1 was treated within two months after transplant and demonstrated significant clinical improvement, normalization of liver function tests (LFTs) and bilirubin, and reduction in donor-specific antibody (DSA) levels following Carfilzomib and TPE. Conversely, Patient 2 was treated more than seven months after the transplant and additionally suffered from chronic cellular rejection with intermittent adherence to outpatient immunosuppressive medications; although DSA levels were marginally reduced following Carfilzomib and TPE, the patient showed minimal clinical improvement, ultimately necessitating a repeat transplant. Overall, Case #1 suggests that Carfilzomib combined with TPE can improve outcomes in select patients especially who have early AMR, while Case #2 highlights critical complicating factors including concomitant disease processes and immunosuppression, thus emphasizing the need for personalizing treatment strategies based on clinical presentation.

2025-07-01·Clinical Lymphoma Myeloma & Leukemia

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

Article

作者: LeBlanc, Richard ; Kaedbey, Rayan ; Su, Jiandong ; White, Darrell ; Mian, Hira ; Reece, Donna ; McCurdy, Arleigh ; Venner, Christopher P ; Stakiw, Julie ; Song, Kevin ; Bergstrom, Debra ; Aslam, Muhammad ; Sebag, Michael ; Chu, Michael P ; Gul, Engin ; Reiman, Anthony ; Kotb, Rami ; Jimenez-Zepeda, Victor H ; Louzada, Martha

INTRODUCTION:

First-line treatment in Canadian transplant-eligible MM patients is CyBorD/RVD followed by ASCT and maintenance lenalidomide. In transplant ineligible patients, bortezomib- or lenalidomide-based treatment is used. Relapse options include salvage ASCT or diverse doublet/triplets. Limited data support any one approach. The aim of this study was to assess treatment patterns/outcomes of real-world patients at first relapse.

METHODS:

All patients initiating second-line therapy from January 1/10 to June 30/22 were included. We evaluated ORR, PFS and OS, calculated from the start of second-line.

RESULTS:

A total of 3569 patients were included, 1638 (45.9%) with prior ASCT and 1931 (54.1%) without. The most used regimens were Rd, DRd, CyBorD, ASCT, RVd and DVd. The highest ORRs were seen with DRd (90%), ASCT (89%), Kd/KCd (79%), RVd (78.1%) and KRd (74%). For drug regimens, median PFS (27.6 months) and OS (75.5 months) were longest for DRd.

CONCLUSIONS:

We evaluated impact of second-line treatment in MM patients. Triplets with an IMiD backbone and carfilzomib combinations had high ORR and durable PFS, with select patients undergoing second ASCT achieving durable responses. Given the expanding use of IMiD, PI and CD38 mAbs frontline, our results highlight the need for modern modalities at first relapse and provide a benchmark for implementation.

423

项与卡非佐米相关的新闻（医药）

2025-06-17

·氨基观察

荣昌生物泰它西普获欧盟孤儿药资格认定；复星医药引进PD-1/IL-2抗体融合蛋白

氨基观察-创新药组原创出品作者 | 黄恺国产重磅自免新药再下一城。6月17日，荣昌生物公告，泰它西普获得欧盟委员会授予的孤儿药资格认定，用于治疗重症肌无力。复星医药引进加速。6月16日，复星医药与Teva（梯瓦）共同宣布，双方通过各自的子公司就在研药物TEV-56278的开发达成战略合作。复星医药将获得TEV-56278在中国（包括港澳台地区）以及特定东南亚国家和地区的独家开发、生产和商业化许可。梯瓦则保留TEV-56278在全球其他地区的开发、生产与商业化权利。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。/ 01 /市场速递1）复星医药引进梯瓦PD-1/IL-2抗体融合蛋白6月16日，复星医药与Teva（梯瓦）共同宣布，双方通过各自的子公司就在研药物TEV-56278的开发达成战略合作。复星医药将获得TEV-56278在中国（包括港澳台地区）以及特定东南亚国家和地区的独家开发、生产和商业化许可。梯瓦则保留TEV-56278在全球其他地区的开发、生产与商业化权利。2）武田制药中国总裁单国洪将离职据21世纪经济报道、南方财经、第一财经等多家媒体消息，武田制药全球高级副总裁、武田制药中国总裁单国洪行将离职，下一站百济神州。/ 02 /资本信息1）柏全生物完成超2亿元A轮融资6月17日，柏全生物宣布完成超两亿元人民币 A 轮融资。此次融资将用于加速公司核心产品——全球首创CD3L1靶点抗肿瘤药物的注册临床试验进程。/ 03 /医药动态1）纽瑞特医疗68Ga-NRT6020注射液获临床许可6月17日，据CDE官网，纽瑞特医疗68Ga-NRT6020注射液获临床许可，用于筛选适合接受177Lu-NRT6020注射液治疗的晚期恶性实体瘤患者。2）赛诺菲Isatuximab注射液（皮下注射）获临床许可6月17日，据CDE官网，赛诺菲Isatuximab注射液（皮下注射）获临床许可，拟联合卡非佐米和地塞米松用于治疗复发和/或难治性多发性骨髓瘤(RRMM)患者。3）泽璟生物注射用ZG005获临床许可6月17日，据CDE官网，泽璟生物注射用ZG005获临床许可，拟联合注射用ZG006用于晚期小细胞肺癌或神经内分泌癌。4）荣昌生物泰它西普获欧盟孤儿药资格认定6月17日，荣昌生物公告，泰它西普获得欧盟委员会授予的孤儿药资格认定，用于治疗重症肌无力。5）首款国产myosin抑制剂启动III期临床6月15日，据全球临床试验收录网站clinicaltrials，恒瑞医药启动了肌球蛋白（myosin）抑制剂HRS-1893的首个III期临床试验。这是首款进入III期阶段的国产肌球蛋白抑制剂，也是唯一一款临床在研国产肌球蛋白抑制剂。/ 04 /海外药闻1）艾伯维Bcl-2抑制剂MDS三期临床失败6月16日，艾伯维宣布。Bcl-2抑制剂维奈克拉+阿扎胞苷联合一线治疗高危骨髓增生异常综合征（HR-MDS）的三期临床VERONA，没有达到OS主要终点。PS：欢迎扫描下方二维码，添加氨基君微信号交流。

孤儿药临床3期

2025-06-13

·药明康德

近100%癌症患者达缓解！百时美施贵宝靶向蛋白降解组合疗法亮眼结果公布

百时美施贵宝（Bristol Myers Squibb）日前在欧洲血液学协会（EHA）年会上，展示了其靶向蛋白降解平台的最新研究数据，包含该公司在研的口服E3泛素连接酶cereblon调节剂（CELMoD）药物mezigdomide（MEZI）和iberdomide（IBER）在多发性骨髓瘤（MM）患者中的更新临床研究结果，以及golcadomide（GOLCA）在非霍奇金淋巴瘤（NHL）中的研究进展。此外，该公司也公布其潜在“first-in-class”的口服BCL6配体导向降解剂（LDD）BMS-986458在NHL中的初步研究结果。值得关注的是，研究数据显示，golcadomide联合利妥昔单抗治疗复发/难治性滤泡性淋巴瘤（R/R FL）患者展现出显著疗效，总缓解率（ORR）高达94%，完全缓解率（CR）为63%，为临床治疗带来新的希望。蛋白降解剂如CELMoD药物和LDD，旨在靶向并降解导致疾病的特定蛋白，包括许多传统小分子抑制剂难以靶向的蛋白。这些创新疗法有望增强现有治疗效果，克服多种恶性疾病中的耐药性，从而改善患者预后。以下为百时美施贵宝在EHA年会期间展示的靶向蛋白降解研究要点：Mezigdomide百时美施贵宝公布了MM-002研究中mezigdomide联合地塞米松及硼替佐米（A组，n=28）和联合地塞米松及卡非佐米（C组，n=27）在复发/难治性多发性骨髓瘤（RRMM）患者中的剂量递增阶段数据。分析显示，A组的ORR为75.0%，C组为85.2%。A组和C组的中位缓解持续时间（DOR）分别为10.9个月（95% CI：8.8–18.7）和11.9个月（95% CI：6.4–35.9）。A组和C组的中位无进展生存期（PFS）分别为12.3个月和13.5个月。此外，研究扩展阶段D组（n=49）在既往接受过1–3种治疗的RRMM患者中的分析结果显示，该患者群体的ORR为85.7%，中位DOR为19.4个月（95% CI：9.7–不可评估），中位PFS为17.5个月。安全性方面，最常见的3/4级治疗伴发不良事件（TEAE）为中性粒细胞减少症，通过使用药物和调整剂量进行管理。图片来源：123RF而mezigdomide联合其他口服创新药物形成三联方案在RRMM患者中的分析数据则显示：Mezigdomide+EZH2抑制剂tazemetostat+地塞米松组合的ORR为50%（n=16）。Mezigdomide+BET抑制剂BMS-986158+地塞米松组合的ORR为35%（n=20）。Mezigdomide+MEK抑制剂trametinib+地塞米松组合的ORR为80%（n=20）。此外，分析显示，上述组合可激活并扩增NK和T细胞，包括既往接受过T细胞重定向疗法的患者。安全性方面，最常见的3/4级TEAE为中性粒细胞减少，非血液学3/4级TEAE较少。IberdomideMM-001研究更新结果显示，iberdomide联合硼替佐米和地塞米松（IberVd）在不适合移植的新确诊多发性骨髓瘤（NDMM）患者中表现出持久且深入的缓解。在中位随访25个月时，意向治疗人群（n=18）的ORR为88.9%，其中66.6%达到CR或更好。此外，44%的CR患者达到最小残留病（MRD）阴性。安全性方面，最常见的3/4级血液学TEAE为中性粒细胞减少（29.4%）；2例（11.8%）出现3/4级外周神经病。总体最常见的3/4级TEAE为感染（47.1%）。Golcadomide评估golcadomide单药或联合利妥昔单抗治疗R/R FL的研究数据更新结果指出，在A部分（剂量递增阶段）中，golcadomide单药治疗患者的ORR为67%，CR率为42%。在B部分（扩展阶段）中，0.4 mg golcadomide联合利妥昔单抗治疗的患者ORR为94%，CR率为63%；中位DOR为4.8个月，中位随访时间为5.75个月。在既往接受来那度胺或T细胞重定向治疗的患者中亦观察到一致反应。安全性方面，B部分（n=60）中最常见的3/4级治疗相关不良事件为中性粒细胞减少（60%）和贫血（13%），未见因不良反应停药，非血液学不良事件较少且多为低等级。而评估golcadomide单药或联合利妥昔单抗治疗复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）的研究结果则显示，使用0.4 mg golcadomide联合利妥昔单抗治疗的患者中，ORR为58%，CR率为44%，中位DOR为14.5个月。而在接受过T细胞重定向疗法的患者中，ORR为56%，CR率为38%。在全部患者（n=77）中最常见的3/4级治疗相关不良事件为中性粒细胞减少（64%）和贫血（20%）。大多数不良事件可控，停药率为7%。根据早期研究结果，mezigdomide、iberdomide和golcadomide正在多个3期研究中进行评估。BMS-986458这次百时美施贵宝也公布了BMS-986458在复发/难治性非霍奇金淋巴瘤患者中的人体初步研究结果。这是一项开放标签、多中心、剂量递增研究，共纳入31例重度经治患者。分析显示，在外周血和肿瘤组织中均观察到BCL6的快速且持久的降解。从最低剂量起即观察到在DLBCL和FL患者中的抗肿瘤活性。在21名可评估疗效的患者中，ORR为81%（N=17），CR率为23.8%（N=5）。此外，BMS-986458的耐受性良好，最常见治疗相关不良事件为1/2级关节痛（19.4%）和疲劳（16.1%）；未观察到≥3级的细胞减少或因不良反应停药。这些积极结果支持该药物的进一步开发。参考资料：[1] Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025. Retrieved June 13, 2025 from https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Presents-Data-Across-Targeted-Protein-Degradation-Research-Including-CELMoD-Agents-and-BCL6-Ligand-Directed-Degrader-at-EHA-2025/default.aspx免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。👇 分享，点赞，在看，聚焦全球生物医药健康创新

临床结果临床研究细胞疗法

2025-06-12

·PipelineReview

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS’ Leadership in Innovative Cancer Therapies PRINCETON, NJ, USA I June 12, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European Hematology Association (EHA) Annual Congress being held from June 12-15 in Milan, Italy. Presentations feature updated clinical findings on the company’s investigational oral CELMoD™ agents mezigdomide and iberdomide in multiple myeloma, and golcadomide in non-Hodgkin lymphoma, as well as the first results evaluating the company’s first-in-class, oral BCL6 ligand-directed degrader (LDD) (BMS-986458) in non-Hodgkin lymphoma. The latest data presented for the three lead CELMoD agents and BCL6 LDD underscore the potential impact that these therapies may have in addressing significant unmet medical needs in hematologic malignancies. These agents are part of continuing research across targeted protein degradation at Bristol Myers Squibb, which also encompasses additional CELMoD agents, LDDs and degrader antibody conjugates (DACs) across blood cancers and solid tumors, as well as non-malignant hematologic disorders. Protein degraders, like CELMoD agents and LDDs, are therapies designed to target and degrade specific proteins that drive diseases, including many proteins that are difficult to target through conventional small-molecule inhibitors. These innovative agents have the possibility to enhance the efficacy of existing therapies and overcome resistance in various malignancies, potentially improving patient outcomes. “As a leader in the field of targeted protein degradation, we are committed to applying our decades of expertise to the development of these next wave of agents. The efficacy and safety data presented at the EHA Annual Meeting this year is promising and reinforces the potential of CELMoD agents in combination with other standard treatments,” said Anne Kerber, Senior Vice President, Head of Development, Hematology, Oncology and Cell Therapy for Bristol Myers Squibb. “These analyses also add to the body of evidence for these programs as we continue pivotal studies for each of the agents that we anticipate reading out in the next year and onwards.” Key targeted protein degradation data being presented by Bristol Myers Squibb at the EHA Annual Congress include: Mezigdomide (MEZI): Abstract #4160130 : Updated results were presented from the dose-escalation phase of the MM-002 study for the combinations of mezigdomide, dexamethasone, and bortezomib (Cohort A MeziVd; n=28), and mezigdomide, dexamethasone, and carfilzomib (Cohort C MeziKd; n=27) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2–4 prior therapies: Results from the dose-expansion cohort (Cohort D) of the study were also presented for the MeziVd combination (n=49) in patients with RRMM who had received 1–3 prior therapies: The most common grade 3/4 treatment-emergent adverse event (TEAE) across arms was neutropenia and was managed with G-CSF and dose modifications. Abstract #4160802 : New data was presented evaluating mezigdomide in all-oral triplet combinations with other oral novel agents in RRMM. Iberdomide (IBER): Abstract #4160144 : Updated results were presented from MM-001, evaluating the combination of iberdomide, bortezomib, and dexamethasone (IberVd) in patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM), confirming durable, deep responses in the study. Golcadomide (GOLCA): Abstract #4160953 : Updated results were presented from a study evaluating golcadomide with or without rituximab for the treatment of R/R follicular lymphoma (FL). Patients with R/R FL who had received ≥2 prior lines of treatment received golcadomide monotherapy in the dose-escalation part of the study (Part A), followed by golcadomide once daily at 0.2 or 0.4 mg with or without rituximab in the expansion part (Part B). Results continued to show promising efficacy with durable responses in heavily pre-treated patients with R/R FL. Abstract #4161005 : Updated results were presented from a study evaluating golcadomide with or without rituximab for the treatment of R/R diffuse large b-cell lymphoma (DLBCL). Patients received golcadomide once daily at either 0.2 mg (n=39) or 0.4 mg (n=38). Results continued to show durable responses in heavily pre-treated patients with R/R DLBCL and a consistent safety profile. Based on the results of early studies, mezigdomide, iberdomide and golcadomide are being evaluated in multiple phase 3 studies: BMS-986458 BCL6 LDD: Abstract #4160340: First clinical findings were presented from the dose-escalation part of the first-in-human, multicenter, open-label study of BMS-986458 in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Initial results evaluating 31 heavily pre-treated patients treated with BMS-986458 were promising and support continued development for the treatment of NHL. Bristol Myers Squibb: Creating a Better Future for People with Cancer Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge capabilities and differentiated research platforms uniquely position the company to approach cancer from every angle. Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , X , YouTube , Facebook and Instagram . SOURCE: Bristol Myers Squibb

临床结果临床3期

100 项与卡非佐米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08880	卡非佐米	L01XX45	DB08889

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Onyx Pharmaceuticals, Inc.	2012-07-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	临床3期	美国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	日本	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	奥地利	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	保加利亚	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	捷克	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	芬兰	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	法国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	德国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	希腊	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	立陶宛	Amgen, Inc.	2019-05-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02659293 (ATLAS, ASCO2025)	临床3期	多发性骨髓瘤维持	81	Carfilzomib, lenalidomide, and dexamethasone (KRd)	鑰糧獵憲夢鹹夢築膚膚(製獵獵鹽鬱衊遞選壓壓) = 網艱壓顧觸廠膚艱艱範襯齋艱願鏇遞憲鹹構鹹 (廠選網艱獵顧餘憲鏇願 ) 更多	积极	2025-05-30
				Lenalidomide (R)	鑰糧獵憲夢鹹夢築膚膚(製獵獵鹽鬱衊遞選壓壓) = 築網齋壓艱遞遞製淵鏇襯齋艱願鏇遞憲鹹構鹹 (廠選網艱獵顧餘憲鏇願 ) 更多
NCT05199311 (phase 1/2 study, ASCO2025)	临床2期	多发性骨髓瘤	38	Carfilzomib, iberdomide, and dexamethasone (KID)	膚憲繭網壓範窪艱鬱鹹(鹹蓋襯鏇選艱艱範願簾) = 遞製齋衊餘糧襯夢鑰廠簾衊鹽繭遞襯餘淵築鹹 (壓遞網鏇衊構淵夢簾膚 ) 更多	积极	2025-05-30
NCT03104842 (GMMG-CONCEPT, ASCO2025)	临床2期	多发性骨髓瘤 HR cytogenetic aberration (CA) (del(17p), t(4;14), t(14;16), ≥3 copies 1q21)	219	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)	淵廠齋蓋齋醖顧顧製積(廠齋憲鑰鬱築構網範簾) = mOS has not been reached 製簾鹹構窪艱淵膚憲構 (衊夢廠鹽顧鹹廠範鹽壓 ) 更多	积极	2025-05-30
ASCO2025	N/A	难治性多发性骨髓瘤	-	Carfilzomib	網憲築鹹鬱網膚糧繭鹽(築構醖衊觸鑰遞憲衊選): aOR = 1.61 (95% CI, 1.48 ~ 1.77), P-Value = < 0.001 更多	不佳	2025-05-30
				No Carfilzomib
NCT04268498 (ADVANCE, ASCO2025)	临床2期	多发性骨髓瘤 minimal residual disease (MRD) positive	306	DKRd (Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone)	積憲鬱醖鏇製醖築憲膚(構餘獵夢鹹艱鏇構顧艱): adjusted OR = 2.5 (95% CI, 1.5 ~ 4.2) 更多	积极	2025-05-30
				KRd (Carfilzomib, Lenalidomide, Dexamethasone)
NCT01863550 (ENDURANCE, ASCO2025)	临床3期	多发性骨髓瘤 del17p \| t(14;16) \| t(14;20) ... 更多	1,087	VRd (Bortezomib, Lenalidomide, Dexamethasone)	夢餘廠憲憲夢簾簾夢廠(積衊壓壓鏇衊醖選艱獵) = 衊鹹觸夢襯窪鬱鏇構艱衊簾蓋齋鹹獵衊壓廠顧 (壓鹽鬱糧衊簾網糧顧鏇 )	积极	2025-05-30
				KRd (Carfilzomib, Lenalidomide, Dexamethasone)	夢餘廠憲憲夢簾簾夢廠(積衊壓壓鏇衊醖選艱獵) = 鬱鹽膚窪繭鬱範餘壓壓衊簾蓋齋鹹獵衊壓廠顧 (壓鹽鬱糧衊簾網糧顧鏇 )
PS1750 (EHA2025)	N/A	难治性多发性骨髓瘤	173	Carfilzomib-Pomalidomide-Dexamethasone	選獵壓製構積糧遞構糧(窪願壓蓋遞觸構簾簾選) = 構齋鑰遞窪齋願餘築餘積簾壓製築蓋廠淵窪鏇 (蓋衊憲鹹遞衊鹹鬱壓築 ) 更多	-	2025-05-14
EMN12/HOVON-129 (EHA2025)	临床2期	浆细胞白血病一线	61	Carfilzomib-lenalidomide-dexamethasone (KRd)	範鹽餘鬱鹹積衊製齋醖(鹹襯壓築鬱顧蓋憲鏇夢) = 鏇顧築壓顧醖醖遞簾簾構憲夢夢廠鑰憲淵鹹蓋 (範顧繭願製選廠範鹽憲 ) 更多	积极	2025-05-14
				High-dose melphalan (HDM) and autologous stem-cell transplantation (ASCT)	範鹽餘鬱鹹積衊製齋醖(鹹襯壓築鬱顧蓋憲鏇夢) = 築選簾鏇鹽鹹鏇夢衊選構憲夢夢廠鑰憲淵鹹蓋 (範顧繭願製選廠範鹽憲 ) 更多
Kydar phase 2 (EHA2025)	临床2期	多发性骨髓瘤二线	41	Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab	鏇蓋糧蓋網襯積構網獵(鬱衊膚衊廠廠遞鑰範醖) = 鏇憲壓窪淵鏇繭醖廠鹹夢齋願衊簾窪餘襯齋製 (製簾憲壓窪壓觸網鹽蓋 ) 更多	-	2025-05-14
NCT02659293 (ATLAS, EHA2025)	临床3期	多发性骨髓瘤维持	-	Carfilzomib, Lenalidomide, and Dexamethasone (KRD)	衊窪獵觸願積壓構範鑰(遞淵膚淵簾壓衊壓窪齋) = 網膚夢願艱憲餘淵艱積願壓遞齋鹹淵膚簾膚繭 (醖蓋壓衊鬱鹽糧願獵餘, 37.3-;HR0.46[95%CI:0.30 ~ 0.70]) 更多	积极	2025-05-14
				Lenalidomide (R) alone	衊窪獵觸願積壓構範鑰(遞淵膚淵簾壓衊壓窪齋) = 繭夢製淵範築製鹽繭簾願壓遞齋鹹淵膚簾膚繭 (醖蓋壓衊鬱鹽糧願獵餘 ) 更多